CN CN
CN CN
Wknife
Wknife
Single Needle & Local Anesthesia
Local anesthesia with a single needle, no need for electrocardiographic synchronization
Minimally Invasive Tumor Technology
Original Technology, Leading the Frontier
Our Technologies>>
Professor Yao pioneered the theory of tumor electroporation twenty years ago
Globally Recognized
In 2000, Professor Yao Chenguo was the first internationally to propose a novel method for tumor ablation using high-voltage, ultra-short pulsed electric field-induced irreversible electroporation (IRE) and elucidated its underlying bioelectromagnetic mechanisms

In 2004, the first international academic journal paper on killing tumor cells with pulsed electric fields was published in IEEE Transactions on Plasma Science, igniting a research surge in pulsed electric field tumor therapy both domestically and globally

Professor Rubinsky, an internationally renowned electroporation expert from the University of California, Berkeley, followed up with related research and collaborated with AngioDynamics to invest in producing the world's first commercial pulsed electric field tumor therapy device—the Nanoknife.
Products
Products
Our Products>>
News
News
MORE >>
Combining "Wknife" with multifunctional nanomedicine to enhance systemic anti-tumor immunity
Recently, Professor Yao Chenguo's team from Chongqing University collaborated with Wu Ming's team from Meng Chao Hepatobiliary Hospital at Fujian Medical University to study the combination of "Wknife" and multifunctional nanomedicine
2023/12 18
Say goodbye to 'carbonized nodules': World's first Wknife ablation of thyroid nodules under local anesthesia achieved
Recently, the Ultrasound Medicine Department of Zhejiang Cancer Hospital successfully implemented the world's first "Wknife" thyroid papillary carcinoma ablation procedure under local anesthesia.
2024/04 23
Good news | The "Wknife" that can ablate tumors under local anesthesia has entered the medical device innovation channel
Recently, the "WKnife" steep pulse ablation device independently developed by Hangzhou V-Onco Medical Technology Co., Ltd. was officially approved by the Medical Device Technical Evaluation Center of the State Medical Products
2025/08 21
Let's go again! Shanghai Yangzhi Rehabilitation Hospital's Comprehensive Surgery Department successfully held the kickoff meeting for the WKnife pulmonary nodule clinical trial project
Recently, Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center) successfully held the kickoff meeting for the "Clinical Trial of Treating Pulmonary Nodules" project of the micro nanosecond collaborative electric
2023/12 05
Embarking on a new journey of WKnife - Guangzhou Fuda Cancer Hospital held a kickoff meeting for the WKnife pulmonary nodule clinical trial project
Recently, Hangzhou V-Onco Medical Technology Co., Ltd. successfully held the kickoff meeting for the "Clinical Trial of the Treatment of Malignant Pulmonary Nodules" project of the Wide Band Collaborative Pulse Ablation Generator
2023/11 30
Hangzhou V-Onco Medical Technology Co., Ltd.
ABOUT US
Hangzhou V-Onco Medical Technology Co., Ltd. is a high-tech company driven by clinical needs to innovate medical technology, dedicated to providing optimal medical solutions for clinical practice.

The company's core technology is based on its entirely self-developed irreversible electroporation (IRE) technology.

Irreversible electroporation (IRE) tissue ablation technology offers significant advantages of being non-thermal and selective. It enables complete ablation of lesions while preserving the integrity of adjacent critical ductal structures, making it a cutting-edge tool for achieving "thorough lesion removal with minimal collateral damage." As such, it is recognized as the next-generation tissue ablation technology.

 V-Onco's R&D team is a pioneer and trailblazer in the theory and practice of tumor irreversible electroporation. Since firstly introducing the novel concept of using irreversible electroporation for tumor treatment internationally in 2000, the team has successively proposed and developed three generations of IRE technology, consistently leading the global advancement and iteration of IRE medical products.
200+

Patent Technology

40+

Core Patents

20+

International Patents